Loading stock data…
$26.09-0.13 (-0.50%)
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases.
Arcutis Biotherapeutics, Inc. in the Healthcare sector is trading at $26.09 with a market capitalization of $3.0B. Wall Street consensus targets $37.00 (7 analysts), implying a +41.8% move over the next 12 months. The stock is currently 18% below its 52-week high of $31.77, remaining 4.0% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 90/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $129.86M↑ | $105.40M↓ | $129.50M↑ | $99.22M↑ | $81.50M |
| Gross Profit | $118.92M↑ | $95.61M↓ | $117.81M↑ | $90.53M↑ | $74.01M |
| Operating Income | $16.43M↑ | -$9.09M↓ | $18.39M↑ | $8.53M↑ | -$14.61M |
| Net Income | $15.01M↑ | -$11.29M↓ | $17.39M↑ | $7.41M↑ | -$15.89M |
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. The company's lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and ...